Document Detail


Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes.
MedLine Citation:
PMID:  20955160     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Type 1 diabetes mellitus is an autoimmune disease against pancreatic β cells. The autoimmune response begins months or years before the clinical presentation. At the time of hyperglycemic symptoms a small amount of β cell mass still remains. The main therapeutic option to type 1 diabetes mellitus is daily insulin injections which is shown to promote tighter glucose control and to reduce much of diabetic chronic complications. Subgroup analysis of the Diabetes Control and Complication Trial (DCCT) showed another important aspect related to long term complications of diabetes, ie, patients with initially larger residual β cell mass suffered less microvascular complications and less hypoglycemic events than those patients with small amounts of β cells at diagnosis. In face of this, β cell preservation has become another important target in the management of type 1 diabetes and its related complications. In this review, we summarize various immunomodulatory regimens ever used in humans, including stem cell-based strategies, aiming at blocking autoimmunity against pancreatic β cells and at promoting β cell preservation and/or possible β cell regeneration in recent-onset type 1 diabetes.
Authors:
Carlos Eduardo Barra Couri; Júlio César Voltarelli
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current stem cell research & therapy     Volume:  6     ISSN:  1574-888X     ISO Abbreviation:  Curr Stem Cell Res Ther     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-11     Completed Date:  2011-05-20     Revised Date:  2012-01-19    
Medline Journal Info:
Nlm Unique ID:  101272517     Medline TA:  Curr Stem Cell Res Ther     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  10-5     Citation Subset:  IM    
Affiliation:
Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Diabetes Mellitus, Type 1 / immunology,  pathology,  therapy*
Humans
Immunomodulation*
Immunosuppressive Agents / therapeutic use
Insulin-Secreting Cells / immunology,  physiology
Regeneration
Stem Cell Transplantation*
Stem Cells / immunology
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autologous hematopoietic stem cell transplantation for systemic sclerosis.
Next Document:  Restoration of the immune balance by autologous bone marrow transplantation in juvenile idiopathic a...